cytarabine + daunorubicin

Cytarabine + daunorubicin is a combination chemotherapy regimen primarily used as induction therapy for acute myeloid leukemia (AML). This specific iteration, often referred to as the AD regimen in trials by the Cooperative Study Group A for Hematology, utilizes a "7+3" schedule consisting of a 7-day continuous infusion of cytarabine and a 3-day course of daunorubicin. Cytarabine acts as a pyrimidine analogue that inhibits DNA polymerase, while daunorubicin is an anthracycline that intercalates DNA and inhibits topoisomerase II. The regimen aims to induce complete remission in patients with previously untreated AML, and in this specific trial context, it was evaluated using a high-dose daunorubicin component (90 mg/m2).

Other names

7+3 regimenDA regimencytarabine and daunorubicin